Outcomes4Me Acquires Geno.Me and Realyze Intelligence, Names UPMC Hillman Cancer Center CIO as Strategic Advisor, to Expedite AI-driven Cancer Care and Clinical Trial Access

Outcomes4Me Inc., a Boston-based health technology company focused on enhancing cancer care through artificial intelligence, has completed its acquisition of Geno.Me, a platform that integrates patient data with research initiatives, and Realyze Intelligence, an AI-driven clinical trial matching platform. The financial details of the transactions remain undisclosed. This strategic move, announced on May 21, 2026, aims to bolster Outcomes4Me's capabilities in providing patients with access to personalized treatment options and clinical trials.

Geno.Me is designed to facilitate immediate access to patient health data, allowing individuals to share their information securely for research and clinical purposes. This integration is particularly significant as it aligns with Outcomes4Me's existing patient empowerment initiatives, which emphasize direct access to evidence-based treatment options without intermediary barriers. Similarly, Realyze Intelligence enhances Outcomes4Me's offerings by utilizing AI to streamline the identification of relevant clinical trial cohorts, thus addressing a critical gap in patient awareness and access to clinical research opportunities.

The acquisition of these platforms comes at a time when the oncology sector is increasingly focusing on patient-centric care and the integration of technology to improve outcomes. By merging the capabilities of Geno.Me and Realyze Intelligence, Outcomes4Me aims to create a comprehensive ecosystem that not only supports cancer patients in navigating their treatment journeys but also contributes to advancing clinical research. The addition of Scot Stevens, Chief Information Officer at UPMC Hillman Cancer Center, as a Strategic Advisor further strengthens the company's position, bringing valuable insights from his extensive experience in health information technology.

The broader implications of these acquisitions suggest a shift towards more integrated and technology-driven approaches in cancer care. As the healthcare landscape evolves, the need for efficient data sharing and clinical trial matching becomes increasingly critical. Outcomes4Me’s enhanced platform is poised to set a new standard in the industry by making cutting-edge cancer care more accessible to patients, thereby driving innovation and improving patient outcomes.

Overall, the combination of Outcomes4Me, Geno.Me, and Realyze Intelligence reflects a growing trend in the health technology sector towards leveraging AI and data integration to empower patients. As the company builds upon its foundation of supporting over 400,000 cancer patients, the potential for transforming the patient experience and advancing clinical research is significant, positioning Outcomes4Me as a leader in the future of precision medicine.